Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | QDPR | P09417 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209914 | 1.00 | ACMSD (0.50) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL9375064 | 0.80 | ESR2 (0.69) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL9313681 | 0.80 | ACMSD (0.53) | ACMSDESR2QDPRHDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL1630000 | 0.79 | ACMSD (0.51) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL68815 | 0.75 | QDPR (0.66) | ACMSDQDPRHDAC4HDAC2HDAC8 | |
| SCHEMBL10884357 | 0.74 | ACMSD (0.57) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL917464 | 0.74 | ACMSD (0.57) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL13072706 | 0.74 | ACMSD (0.57) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL21630424 | 0.74 | ACMSD (0.57) | ACMSDESR2QDPRHDAC4HDAC2 | |
| SCHEMBL10890219 | 0.74 | ACMSD (0.57) | ACMSDESR2QDPRHDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194147-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-6465497-B2 | SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1194147-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6380191-B1 | FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO. INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1194147-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2000078313-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | PPARD, PPARA, PPARG | ACMSD 3109/4885ESR2 245/4885QDPR 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.